Literature DB >> 9365087

The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

V D Steen1, T A Medsger.   

Abstract

OBJECTIVE: To determine the validity and usefulness of a modified Health Assessment Questionnaire (HAQ) for measurement of disease status and changes in disease status over time in patients with systemic sclerosis (SSc).
METHODS: Since 1985, 1,250 patients attending the University of Pittsburgh Scleroderma Clinic have completed a modified HAQ annually. In addition to the standard HAQ questions about disability, the questionnaire includes visual analog scales (VAS) to evaluate SSc organ system symptoms, Raynaud's phenomenon, gastrointestinal (GI) tract and lung involvement, pain, and overall disease severity. In this study, the disability index (DI) (from the HAQ) and the VAS scores (on a 0-3 scale) were compared with various clinical and laboratory features recorded within 3 months of administration of the HAQ and VAS, using t-tests and Spearman's correlation tests.
RESULTS: The HAQ DI correlated directly with skin involvement, scleroderma heart or kidney disease, tendon friction rubs, hand contractures, and proximal muscle strength. Over time, the DI correlated with changes in skin score and was a good predictor of survival. There was a significant improvement in the DI during a 2-year time period in patients treated with D-penicillamine. The VAS for digital ulcers, GI symptoms, and lung symptoms correlated very closely with subjective and objective findings for these organ systems. The presence of new digital ulcers or improvement in digital ulcers showed significant associations with the Vascular scale, new GI symptoms or improvement in GI symptoms and institution of H2-blockers showed appropriate strong correlations with the GI scale, and changes in the forced vital capacity had an excellent correlation with the Lung scale (r = 0.58, P < 0.001). By Cox regression analysis, the HAQ DI was one of the best predictors of survival.
CONCLUSION: These data provide convincing evidence that a self-administered questionnaire is an accurate and inexpensive tool to measure disease status changes in SSc. Prospective studies with the HAQ administered at regular intervals, as in controlled trials, should be performed to further assess the benefits and limitations of this instrument.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365087     DOI: 10.1002/art.1780401110

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  114 in total

Review 1.  Combination therapies for systemic sclerosis.

Authors:  C P Denton; C M Black
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis.

Authors:  Monique E Hinchcliff; Jennifer L Beaumont; Mary A Carns; Sofia Podlusky; Krishna Thavarajah; John Varga; David Cella; Rowland W Chang
Journal:  J Rheumatol       Date:  2014-11-01       Impact factor: 4.666

3.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

4.  Functional limitations and well-being in injured municipal workers: a longitudinal study.

Authors:  Marion Gillen; Sarah A Jewell; Julia A Faucett; Edward Yelin
Journal:  J Occup Rehabil       Date:  2004-06

5.  Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Authors:  P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold
Journal:  Arthritis Rheum       Date:  2012-10

6.  Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ).

Authors:  C Georges; O Chassany; L Mouthon; K Tiev; C Toledano; O Meyer; Z Marjanovic; C Heneggar; T Papo; B Crickx; D Sereni; J Cabane; D Farge
Journal:  Clin Rheumatol       Date:  2004-06-23       Impact factor: 2.980

7.  Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays
Journal:  Qual Life Res       Date:  2007-04-03       Impact factor: 4.147

8.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlie Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fred Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li
Journal:  Am J Respir Crit Care Med       Date:  2007-08-23       Impact factor: 21.405

9.  Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Authors:  Linda Kwakkenbos; Brett D Thombs; Dinesh Khanna; Marie-Eve Carrier; Murray Baron; Daniel E Furst; Karen Gottesman; Frank van den Hoogen; Vanessa L Malcarne; Maureen D Mayes; Luc Mouthon; Warren R Nielson; Serge Poiraudeau; Robert Riggs; Maureen Sauvé; Fredrick Wigley; Marie Hudson; Susan J Bartlett
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

10.  What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Authors:  Xiangning Fan; Janet Pope; Murray Baron
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.